Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Eltrombopag 25 mg
DRUG
2 trials
Sponsors
Novartis Pharmaceuticals
, Renata PLC
Conditions
Cytopaenia
Primary Immune Thrombocytopenia
Phase 1
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
Recruiting
NCT06531018
Renata PLC
Primary Immune Thrombocytopenia
Start: 2025-02-07
End: 2025-12-31
Target: 100
Updated: 2025-02-18
Phase 2
A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
Completed
NCT02148133
Novartis Pharmaceuticals
Cytopaenia
Start: 2014-07-23
End: 2017-09-05
Updated: 2019-05-03
Related Papers
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
2019-06-10
29 citations